Trial Profile
An Open Label, Randomized, Multicenter study to Evaluate and Compare the Immunogenicity and Reactogenicity of DTwP-Hib-IPV vaccine (EasyfourPolTM, Panacea Biotec Ltd.) with QuadrovaxTM (Tetravalent DTwP/Hib Vaccine, Serum Institute of India Ltd.) Co Administered with Imovax Polio® (Salk Based Inactivated Polio Vaccine, Sanofi Pasteur India Pvt. Ltd.) in Healthy Infants. - Easyfour Pol Study
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Hib-DTP-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Panacea Biotec
- 30 Aug 2016 New trial record